Lobbying by Boehringer Ingelheim Canada Ltd.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← Lobbying
Corporation
Boehringer Ingelheim Canada Ltd.
Meetings this Parliament
18
With MPs
5
Since Nov 2021
45
Active registrations
1
Dec 2024 Reports per month Nov 2026
Most recent reported meeting: Sep 21, 2026.
Who they meet
Since the current Parliament opened.
Institutions
Health Canada (HC) 9
Innovation, Science and Economic Development Canada (ISED) 5
House of Commons 5
Finance Canada (FIN) 2
Treasury Board Of Canada Secretariat (TBS) 1
Senate of Canada 1
Privy Council Office (PCO) 1
Global Affairs Canada (GAC) 1
Registrations in effect
In-house (corporation)
In effect since Aug 18, 2026
Filed by Rithesh Mishra , Interim President and CEO
Lobbyists
Andrew Ransom · Manager, Patient Access
Annie Beauchemin · Head, Market Access
Brad Thompson · Manager, External & Healthcare Affairs
Eve Blanchet · Regional Manager/ QUE, Patient Access and Health Policy
James Thompson · Manager, National Health Policy
Mehmood Alibhai · Director of Patient Access & Healthcare Policy
Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (2) Hide details
Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB). Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Registration 965031-371995-12. Look it up in the official Registry
Filed by Mark Lewis (27), Andrea Sambati (11), Rithesh Mishra (5), Ruta Stauskas (2).
Sep 21, 2026
Reported by Rithesh Mishra · In-house (corporation)
Lori Idlout · Member of Parliament
Benjamin Wiles · Chief of Staff, House of Commons
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Jul 14, 2026
Reported by Rithesh Mishra · In-house (corporation)
Raquel Dancho · Member of Parliament
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Jun 15, 2026
Reported by Rithesh Mishra · In-house (corporation)
Dan Mazier · Member of Parliament
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Jun 5, 2026
Reported by Rithesh Mishra · In-house (corporation)
Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Jun 5, 2026
Reported by Rithesh Mishra · In-house (corporation)
Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Apr 22, 2026
Reported by Mark Lewis · In-house (corporation)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Jocelyn Milburn · Director, Policy, Innovation, Science and Economic Development Canada (ISED)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Mar 31, 2026
Reported by Mark Lewis · In-house (corporation)
Justine Frame · Special Assistant, Policy,, Health Canada (HC)
Jibril Hussein · Policy Analyst, Health Canada (HC)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Mar 24, 2026
Reported by Mark Lewis · In-house (corporation)
Maggie Chi · Member of Parliament
Justine Frame · Special Assistant, Policy,, Health Canada (HC)
Jibril Hussein · Policy Advisor, Health Canada (HC)
nora draper · Parliamentary Secretary Assistant;, Health Canada (HC)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Jan 13, 2026
Reported by Mark Lewis · In-house (corporation)
Justine Frame · Special Assistant, Policy,, Health Canada (HC)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Jan 8, 2026
Reported by Mark Lewis · In-house (corporation)
Ritu Banerjee · ADM, Innovation, Science and Economic Development Canada (ISED)
Jocelyn Milburn · Director, Policy, Innovation, Science and Economic Development Canada (ISED)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Dec 1, 2025
Reported by Mark Lewis · In-house (corporation)
Karim Bardeesy · MP
Miro Froehlich · Director of Policy, Privy Council Office (PCO)
Nasser Haidar · Senior Policy Advisor, Privy Council Office (PCO)
Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
and 14 more Show fewer
Peter M. Boehm · Senator, Senate of Canada
Martin Moen · Associate Assistant Deputy, Global Affairs Canada (GAC)
Ritu Banerjee · ADM, Innovation, Science and Economic Development Canada (ISED)
Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Hosai Zurmati Halim · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Chase Knight · Parliamentary Secretary, Innovation, Science and Economic Development Canada (ISED)
Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
victoria morton · Senior Communications Advisor,, House of Commons
Greg Orencsak · Deputy Minister, Health Canada (HC)
sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Justine Frame · Special Assistant, Policy,, Health Canada (HC)
Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).
Official report
Nov 17, 2025
Reported by Mark Lewis · In-house (corporation)
Shadad Khallidi · Deputy director of policy, Health Canada (HC)
Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).
Official report
Oct 27, 2025
Reported by Mark Lewis · In-house (corporation)
Ritu Banerjee · ADM, Innovation, Science and Economic Development Canada (ISED)
Rodrigo Arancibia · Executive Director, Innovation, Science and Economic Development Canada (ISED)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Sep 24, 2025
Reported by Mark Lewis · In-house (corporation)
Manuela Tomic · Senior policy advisor, Innovation, Science and Economic Development Canada (ISED)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Sep 9, 2025
Reported by Mark Lewis · In-house (corporation)
luke carter · Manager, Health Canada (HC)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Sep 9, 2025
Reported by Mark Lewis · In-house (corporation)
Mike Poitras · Director, Health Canada (HC)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Sep 9, 2025
Reported by Mark Lewis · In-house (corporation)
Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
Luke Carter · Executive Director, Health Canada (HC)
Russell Vallee · Manager, Health Canada (HC)
Mike Poitras · Director, Health Canada (HC)
and 1 more Show fewer
elisha hurlock · Manager, Health Canada (HC)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Aug 25, 2025
Reported by Mark Lewis · In-house (corporation)
Max Lee · Senior Communications Advisor, Health Canada (HC)
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Oct 21, 2024
Reported by Mark Lewis · In-house (corporation)
Kim Pate · Senator, Senate of Canada
Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.
Official report
Sep 26, 2024
Reported by Mark Lewis · In-house (corporation)
Marcus Powlowski · Member of Parliament
Health
Official report
Aug 27, 2024
Reported by Mark Lewis · In-house (corporation)
william fassett · Office Manager, House of Commons
Simon Wood · Legislative Assistant, House of Commons
Health
Official report
Jun 11, 2024
Reported by Mark Lewis · In-house (corporation)
Sean Casey · Member of Parliament
Robert Kitchen · Member of Parlilament, House of Commons
Health
Official report
Apr 17, 2024
Reported by Mark Lewis · In-house (corporation)
Jade Mallette · Director of Parliamentary Affairs, House of Commons
Health
Official report
Mar 22, 2024
Reported by Mark Lewis · In-house (corporation)
Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
Health
Official report
Mar 22, 2024
Reported by Mark Lewis · In-house (corporation)
Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Health
Official report
Page 1
Older →
From the Office of the Commissioner of Lobbying's open data , published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence .
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.
Glossary
Compare bills
★ My bills
Data from LEGISinfo ,
the House of Commons
and Open North's Represent .
Proposed changes are the opening summary printed with each bill. The other lines are built from the bill's listed title and status.
Lobbying data from the Office of the Commissioner of Lobbying .
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying .